Elad Sharon (@EladSharonMD) header
Elad Sharon (@EladSharonMD) profile picture

Elad Sharon

@EladSharonMD

#AssocProf of Medicine @DanaFarber posting on #immunotherapy, #drugdevelopment, #irAEs & #HealthEcon. Formerly @theNCI & #CancerMoonshot Adult ImmunoTx Co-Chair

 Boston, MA
Joined March 2017
  • Tweets42.5K
  • Following4.5K
  • Followers4.2K
831Media
Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)Photo by Elad Sharon (@EladSharonMD)
The 2020 @AACR-@NIH Joint Conference on #Cancer, #Autoimmunity & #Immunology from March 2020 is freely available and online! Lots of great talks!! aacr.org/professionals/polic… @theNCI @NIDDKgov @NIAIDNews @NIH_NIAMS @NCICTEP_ClinRes @NCItreatment

NIH-AACR Cancer, Autoimmunity, and Immunology Conference Recordings

Archived recording of the virtual 2020 NIH-AACR Cancer, Autoimmunity, and Immunology Conference.

aacr.org
5
4
1
75
Elad Sharon retweeted
Shilpa Gupta (@shilpaonc) profile picture
Shilpa Gupta
@shilpaoncOct 26
Huge congratulations @neerajaiims & entire TALAPRO-3 team on the FDA approval of talazoparib-enza ! 🎉👏 A major milestone for precision medicine in mHSPC! @AzadOncology @quimmateo @PCFnews @OncoAlert @montypal @DrChoueiri @PGrivasMDPhD @Uromigos @ChrisSweens1
Neeraj Agarwal, MD, FASCO (@neerajaiims) profile pictureNeeraj Agarwal, MD, FASCO
@neerajaiimsOct 26
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
2
13
33
1,529
Elad Sharon retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 26
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu #ESMO26 | @myESMO
A graph shows progression-free survival as assessed by blinded independent central review.

ALT A graph shows progression-free survival as assessed by blinded independent central review.

A graph showing overall survival in the intention-to-treat population.

ALT A graph showing overall survival in the intention-to-treat population.

3
33
2
116
17,978
Elad Sharon retweeted
Sara Tolaney (@stolaney1) profile picture
Sara Tolaney@stolaney1Oct 26
IT trastuzumab and pertuzumab for HER2+ LMD (Pts could continue treatment with HER2-directed systemic therapy) @OncoAlert #ESMO26
Image from Sara Tolaney (@stolaney1)
3
26
4
50
5,878
See you soon at @myESMO
Image from G Curigliano MD PhD (@curijoey)
14
4
133
8,201
Elad Sharon retweeted
Zihai Li, MD, PhD (@Zihai) profile picture
Zihai Li, MD, PhD@ZihaiOct 28
Replying to @OhioStatePIIO
@OhioStatePIIO welcomes Dr. Giorgio Trinchieri to @OSUCCC_James @OhioState as a distinguished seminar speaker! A wonderful evening with colleagues, sharing great food and conversation about life, microbiome and cancer immunology.
Image from Zihai Li, MD, PhD (@Zihai)
2
22
844
Further evidence for the CNS efficacy of TDXd from DB09 and @CristinaSaura3 #ESMO26 @OncoAlert
Image from Stephanie Graff, MD, FACP, FASCO (@DrSGraff)
Image from Stephanie Graff, MD, FACP, FASCO (@DrSGraff)
Image from Stephanie Graff, MD, FACP, FASCO (@DrSGraff)
13
18
949
But the most important part is that she is the first woman pregnant to run a plenary. A role model for all women who think that they can do It! #ESMOAmbassadors @DrJNaidoo #womenforoncology
Stephen V Liu, MD (@StephenVLiu) profile pictureStephen V Liu, MD
@StephenVLiuOct 26
The lung cancer community at #ESMO26 Presidential Symposium III here for Dr. Jarushka Naidoo (+1) @DrJNaidoo - discussant on phase III trial of reduced frequency IO. One of the most brilliant minds in our field - always insightful, thoughtful, balanced. #ESMOAmbassadors @myESMO
Image from Stephen V Liu, MD (@StephenVLiu)
2
15
50
1,838
Elad Sharon retweeted
Ron Alfa (@Ronalfa) profile picture
Ron Alfa
@RonalfaOct 26
awesome result for sarcoma patients, very clear signal for this target in our cohorts.
Paolo Tarantino (@PTarantinoMD) profile picturePaolo Tarantino
@PTarantinoMDOct 26
For the first time, ADCs deliver a statistically positive truck test in sarcomas! 🛻
Image from Paolo Tarantino (@PTarantinoMD)
1
20
1,818
#ESMO26 Wonderful Presidential Dinner with friends @MartinReck2 @HendriksLizza @t_mitsudomi @AndrearicFili @JordiRemon @AyaHelali @alshamsi2000 @VivekSubbiah
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
8
100
5,822
Elad Sharon retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 26
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) nej.md/4BiCvbk #ESMO26 | @myESMO
A graph showing progression-free survival, as assessed by blinded independent central review, among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

ALT A graph showing progression-free survival, as assessed by blinded independent central review, among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

A graph showing overall survival among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

ALT A graph showing overall survival among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

1
38
5
98
19,605
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Neeraj Agarwal, MD, FASCO (@neerajaiims) profile pictureNeeraj Agarwal, MD, FASCO
@neerajaiimsMay 30
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
6
47
4
125
8,313
Leaving beautiful Madrid with renewed energy and enthusiasm! Amazing conversations, reunions, practice-changing data, and art! #ESMO26 @OncoAlert
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
4
16
1
105
8,862
#ESMO26 Dr. Jarushka Naidoo @DrJNaidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations. And for MOIO in particular - lessons on trial design, non-inferiority, and pragmatism. A must-listen to all involved in trial design. #ESMOAmbassadors
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
2
23
1
52
3,944
Elad Sharon retweeted
Adam C Palmer (@ac_palmer) profile picture
Adam C Palmer@ac_palmerOct 26
Anyone interested in cancer medicine needs to see the current front page of @NEJM nejm.org It's one historic advance after another after another on there right now
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
22
177
19
836
55,194
Honored to have the opportunity to present the results from our translational #CHARISMA study, unveiling mechanisms of resistance to TOPO1 ADC. A true team work involving the amazing @DFCI_BreastOnc research teams and @AstraZeneca Translational Medicine. 🧬 #ESMO26
Dana-Farber (@DanaFarber) profile pictureDana-Farber
@DanaFarberOct 26
.@PTarantinoMD, PhD, presents research using paired-biopsy multi-omic analysis to uncover target-independent mechanisms of antibody–drug conjugate (ADC) resistance in metastatic breast cancer. #ESMO26
Image from Dana-Farber (@DanaFarber)
5
26
2
97
5,469
Elad Sharon retweeted
Dana-Farber (@DanaFarber) profile picture
Dana-Farber
@DanaFarberOct 24
The second day of poster presentations at #ESMO26 featured research on breast, CNS tumors, and melanoma.
Image from Dana-Farber (@DanaFarber)
Image from Dana-Farber (@DanaFarber)
Image from Dana-Farber (@DanaFarber)
Image from Dana-Farber (@DanaFarber)
3
16
1
82
5,025
Replying to @MDAndersonnews
@MDAndersonnews Faculty: Join us TOMORROW, Oct. 26 (11am - 3 pm), for the Faculty Career Expo Pickens Ballrooms & Lantern Cafe & FCS! Connect with colleagues & explore many career resources. At noon: “Leading thru Life,” a fireside chat with Dr. Robin Zon, past ASCO president. Don’t miss it! #EndCancer
Image from Anne Tsao, MD, MBA (@AnneTsao2)
3
1
9
749
Best part of any meeting is the post meeting discussion is data while enjoying the local cuisine @hmcarthur @KateIdaLathrop #esmo2026
Image from VIRGINIA KAKLAMANI (@VKaklamani)
4
48
1,424
Elad Sharon retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 25
Original Article: Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer (phase 3 HEALER trial) nej.md/4BcWlF3 Editorial: Targeting HER2 — A Triumph of Science nej.md/4Bh4GaF #ESMO26 | @myESMO
Two panels showing progression-free survival, overall and according to subgroup analyses (intention-to-treat population). Panel A is a graph showing progression-free survival as assessed by blinded independent central review; data are presented as stratified hazard ratio and 95% confidence interval. Panel B is a forest plot showing blinded independent central review–assessed progression-free survival in prespecified subgroups; data are presented as unstratified hazard ratios and 95% confidence intervals.

ALT Two panels showing progression-free survival, overall and according to subgroup analyses (intention-to-treat population). Panel A is a graph showing progression-free survival as assessed by blinded independent central review; data are presented as stratified hazard ratio and 95% confidence interval. Panel B is a forest plot showing blinded independent central review–assessed progression-free survival in prespecified subgroups; data are presented as unstratified hazard ratios and 95% confidence intervals.

2
38
3
94
26,016
Packed house for @lewisjwau education session on tumour microenvironment 🤩 #ESMO26 @McArthurLab @PMPostdocs
Image from Annie Wong 黃毅敏 (@anmwongNZ)
Image from Annie Wong 黃毅敏 (@anmwongNZ)
1
5
13
585
Load more